Literature DB >> 21642949

Drug discovery for polycystic kidney disease.

Ying Sun1, Hong Zhou, Bao-xue Yang.   

Abstract

In polycystic kidney disease (PKD), a most common human genetic diseases, fluid-filled cysts displace normal renal tubules and cause end-stage renal failure. PKD is a serious and costly disorder. There is no available therapy that prevents or slows down the cystogenesis and cyst expansion in PKD. Numerous efforts have been made to find drug targets and the candidate drugs to treat PKD. Recent studies have defined the mechanisms underlying PKD and new therapies directed toward them. In this review article, we summarize the pathogenesis of PKD, possible drug targets, available PKD models for screening and evaluating new drugs as well as candidate drugs that are being developed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21642949      PMCID: PMC4009953          DOI: 10.1038/aps.2011.29

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  111 in total

1.  Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion.

Authors:  Tonghui Ma; Jay R Thiagarajah; Hong Yang; Nitin D Sonawane; Chiara Folli; Luis J V Galietta; A S Verkman
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

2.  A defect in a novel Nek-family kinase causes cystic kidney disease in the mouse and in zebrafish.

Authors:  Shanming Liu; Weining Lu; Tomoko Obara; Shiei Kuida; Jennifer Lehoczky; Ken Dewar; Iain A Drummond; David R Beier
Journal:  Development       Date:  2002-12       Impact factor: 6.868

3.  The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia.

Authors:  Bradley K Yoder; Xiaoying Hou; Lisa M Guay-Woodford
Journal:  J Am Soc Nephrol       Date:  2002-10       Impact factor: 10.121

4.  Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat.

Authors:  R D Gile; B D Cowley; V H Gattone; M P O'Donnell; S K Swan; J J Grantham
Journal:  Am J Kidney Dis       Date:  1995-09       Impact factor: 8.860

5.  Trans-heterozygous Pkd1 and Pkd2 mutations modify expression of polycystic kidney disease.

Authors:  Guanqing Wu; Xin Tian; Sayoko Nishimura; Glen S Markowitz; Vivette D'Agati; Jong Hoon Park; Lili Yao; Li Li; Lin Geng; Hongyu Zhao; Winfried Edelmann; Stefan Somlo
Journal:  Hum Mol Genet       Date:  2002-08-01       Impact factor: 6.150

6.  Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.

Authors:  Vincent H Gattone; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

7.  Mutations in INVS encoding inversin cause nephronophthisis type 2, linking renal cystic disease to the function of primary cilia and left-right axis determination.

Authors:  Edgar A Otto; Bernhard Schermer; Tomoko Obara; John F O'Toole; Karl S Hiller; Adelheid M Mueller; Rainer G Ruf; Julia Hoefele; Frank Beekmann; Daniel Landau; John W Foreman; Judith A Goodship; Tom Strachan; Andreas Kispert; Matthias T Wolf; Marie F Gagnadoux; Hubert Nivet; Corinne Antignac; Gerd Walz; Iain A Drummond; Thomas Benzing; Friedhelm Hildebrandt
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

8.  Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells.

Authors:  Surya M Nauli; Francis J Alenghat; Ying Luo; Eric Williams; Peter Vassilev; Xiaogang Li; Andrew E H Elia; Weining Lu; Edward M Brown; Stephen J Quinn; Donald E Ingber; Jing Zhou
Journal:  Nat Genet       Date:  2003-01-06       Impact factor: 38.330

9.  Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD.

Authors:  J Du; P D Wilson
Journal:  Am J Physiol       Date:  1995-08

10.  Gender-dependent disease severity in autosomal polycystic kidney disease of rats.

Authors:  N Gretz; I Ceccherini; B Kränzlin; I Klöting; M Devoto; P Rohmeiss; B Hocher; R Waldherr; G Romeo
Journal:  Kidney Int       Date:  1995-08       Impact factor: 10.612

View more
  15 in total

1.  Green mamba peptide targets type-2 vasopressin receptor against polycystic kidney disease.

Authors:  Justyna Ciolek; Helen Reinfrank; Loïc Quinton; Say Viengchareun; Enrico A Stura; Laura Vera; Sabrina Sigismeau; Bernard Mouillac; Hélène Orcel; Steve Peigneur; Jan Tytgat; Laura Droctové; Fabrice Beau; Jerome Nevoux; Marc Lombès; Gilles Mourier; Edwin De Pauw; Denis Servent; Christiane Mendre; Ralph Witzgall; Nicolas Gilles
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-19       Impact factor: 11.205

2.  Analysis of catechol-O-methyltransferase gene mutation and identification of new pathogenic gene for paroxysmal kinesigenic dyskinesia.

Authors:  Chengzhi Gu; Jia Li; Lianhai Zhu; Zhenhui Lu; Huaiyu Huang
Journal:  Neurol Sci       Date:  2015-12-09       Impact factor: 3.307

3.  Channelopathies and drug discovery in the postgenomic era.

Authors:  Dayue Darrel Duan; Tong-hui Ma
Journal:  Acta Pharmacol Sin       Date:  2011-06       Impact factor: 6.150

Review 4.  An approach to cystic kidney diseases: the clinician's view.

Authors:  Christine E Kurschat; Roman-Ulrich Müller; Mareike Franke; David Maintz; Bernhard Schermer; Thomas Benzing
Journal:  Nat Rev Nephrol       Date:  2014-09-30       Impact factor: 28.314

5.  Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels.

Authors:  Matthew Tan; Hiromi I Wettersten; Kristy Chu; David L Huso; Terry Watnick; Sharon Friedlander; Yosef Landesman; Robert H Weiss
Journal:  Am J Physiol Renal Physiol       Date:  2014-09-18

6.  Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.

Authors:  Linda Xiaoyan Li; Lucy X Fan; Julie Xia Zhou; Jared J Grantham; James P Calvet; Julien Sage; Xiaogang Li
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

7.  Ginkgolide B inhibits renal cyst development in in vitro and in vivo cyst models.

Authors:  Hong Zhou; Jinsheng Gao; Li Zhou; Xin Li; Weidong Li; Xuejun Li; Yin Xia; Baoxue Yang
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-15

8.  NHA2 promotes cyst development in an in vitro model of polycystic kidney disease.

Authors:  Hari Prasad; Donna K Dang; Kalyan C Kondapalli; Niranjana Natarajan; Valeriu Cebotaru; Rajini Rao
Journal:  J Physiol       Date:  2018-10-17       Impact factor: 5.182

9.  Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study.

Authors:  Andrew P McGovern; Simon Jones; Jeremy van Vlymen; Anand K Saggar; Richard Sandford; Simon de Lusignan
Journal:  BMC Nephrol       Date:  2014-11-20       Impact factor: 2.388

10.  Influence of angiotensin converting enzyme (ACE) gene rs4362 polymorphism on the progression of kidney failure in patients with autosomal dominant polycystic kidney disease (ADPKD).

Authors:  Gnanasambandan Ramanathan; Santu Ghosh; Ramprasad Elumalai; Soundararajan Periyasamy; Bhaskar V K S Lakkakula
Journal:  Indian J Med Res       Date:  2016-06       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.